As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

Lars Rebien Sorensen becomes CEO after serving as the head of Novo's healthcare business. The company's enzymes business was ...

When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge ...

Our premium News+ ad-free experience – only $10 more every 4 weeks!

Novo Nordisk says an oral drug which can help type 2 diabetes patients to lower their blood sugar, substantially lower their risk of having a heart attack or stroke, and help them lose weight ...

Novo Nordisk said the Food and Drug Administration ... Last month, Eli Lilly said its oral obesity and type 2 diabetes treatment, called orforglipron, met its goals in the first of several studies ...

which is FDA-approved for diabetes. One stock that probably won't stay cheap With Wegovy in its portfolio, Novo Nordisk is a very good bet to continue being a winner. As it's currently considered ...

And right now, the cheapest GLP-1 stock is Novo Nordisk's. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor ...

Novo Nordisk is definitely battling with competition, as can be seen in the stagnation in the GLP-1, Insulin and total diabetes market share after 2022. However, the achieved growth rates were ...

Shelby Knowles/Bloomberg News Novo Nordisk sparked the obesity drug revolution with Ozempic and Wegovy. Now it’s racing to avoid falling further behind Eli Lilly. On Monday, Novo announced new ...

Novo Nordisk A/S is partnering with telehealth companies including Hims & Hers Health Inc., LifeMD Inc., and Ro to offer weight-loss drug Wegovy at lower price. Novo Nordisk A/S is partnering with ...